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INTRODUCTION
The role of Helicobacter pylori in various gastroduode-
nal pathologies, including gastritis, duodenal ulcer, gastric
ulcer, stomach cancer, and stomach mucosa-associated
lymphoid tissue (MALT)oma, has led to the development
of many diagnostic methods for detecting H. pylori in the
stomach, both invasive and non-invasive[1-3]. Among
the non-invasive tests, the 13C-urea breath test (13C-UBT),
first introduced by Graham et al. in 1987, is one of the
most important, accurate, and commonly used methods
for detecting H. pylori infection[4]. Due to its excellent
diagnostic accuracy, the 13C-UBT has been promoted as
the preferable method for confirming eradication as well
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Background : The urea breath test (UBT) is regarded as a highly reliable, noninvasive tool for diag-
nosing Helicobacter pylori infection. We compared a recently developed low-dose 38 mg 13C-urea
capsule, which is able to eliminate oral urease effects and does not require positional changes dur-
ing the test, with the conventionally used 100 mg 13C-urea tablet method.
Methods : Thirty-nine volunteers were tested under informed consent with both 13C-UBT methods,
Helifinder� and UBiT-IR300�, with a minimum 2-week washout period. The pre-ingestion and 20-
minute post-ingestion breath samples were analyzed with an isotope ratio mass spectrometer for
Helifinder, and a nondispersive isotope-selective infrared spectrophotometer for UBiT samples.
Results : Helifinder method showed excellent agreement with UBiT among 19 positive and 20
negative cases (weighted kappa value, 1.0). Helifinder results (y) showed good agreement but with
a proportional bias compared to UBiT results (x) by Passing and Bablok method (y=0.551x-0.255,
r=0.74, P<0.0001).
Conclusions : Since the low-dose 38 mg 13C-urea capsule (Helifinder) test, which is more conve-
nient and economic, showed comparable results with the conventional UBiT method, it can be used
as an alternative for the diagnosis of H. pylori infection. (Korean J Lab Med 2006;26:81-5)
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as epidemiological investigations[5-7]. The 13C-UBT is
based on the capacity of the H. pylori urease to hydrolyze
urea to ammonia and carbon dioxide, which diffuses into
the blood, and is excreted by the lungs. Thus, by labeling
urea with 13C, the presence of H. pylori in the stomach
can be identified by detecting 13C in the expired breath
sample with measuring equipments such as an isotope
ratio mass spectrometer (IRMS), a nondispersive isotope-
selective infrared spectroscopy (NDIRS), or a laser-assist-
ed ratio analysis (LARA). During recent years, the 13C-
UBT has made several modifications to provide a more
innocuous, simplified, and applicable procedure to be used
in the clinical setting. Although the 14C-labelled urea can
also be utilized for UBTs, this radioactive isotope brought
up problems dealing with hospital department licensing for
storage and disposal of radioactive substrates and, more
importantly, radiation exposure for the patients[8, 9]. In
contrast, the non-radioactive stable isotope 13C is innocu-
ous enough that the 13C-UBT can be repeated as often
as required in the same patient and can also be safely
performed in children and women of child-bearing age.
Moreover, lowering the dose of 13C is an advantageous
attempt to provide a more risk-free UBT technique for
H. pylori detection.
In this study, we compared a recently developed low-
dose urea capsule that uses an IRMS system with the
conventional 13C-UBT for detection of H. pylori infection.
The currently used UBiT method was employed as the
reference standard since a growing number of studies with
favorable results for this tablet-based 13C-UBT implement-
ing the NDIRS have been reported[10, 11].
MATERIALS AND METHODS
1. Study population
Apparently healthy volunteers were recruited for the
comparative 13C-UBT study. On receiving approval from
the Institutional Review Board (IRB), the study was con-
ducted from November 2004 until January 2005. Partici-
pants who had a history of treatment with antibacterial
agents, proton pump inhibitors, histamine receptor antag-
onists, bismuth preparations, and ecabet sodium prepara-
tions within 4 weeks prior to the start of the study were
excluded. Other exclusion criteria included a history of
gastric surgery, possible or current pregnancy, participa-
tion in a clinical study within 4 weeks prior to the start
of this study, alcoholism or drug abuse, and pulmonary
abnormalities such as asthma or chronic pneumonia. All
thirty-nine subjects submitted their written informed con-
sent prior to testing. 
2. Study phases
The low-dose 38 mg 13C-urea capsule (Helifinder�;
InBioNet Pharmaceutical, Ichon, Korea) method was tested
followed by a 2-week washout period before performing
the 13C-UBT using the 100 mg 13C-urea tablets (UBiT�;
Otsuka Pharmaceutical, Tokyo, Japan). Both urea breath
tests required a minimum of 4-hour overnight fasting prior
to testing for all participants. 13C was measured as the
13CO2:12CO2 isotope ratio and expressed as delta over base-
line (DOB) per mil ( ).
The first phase of the study protocol was done by urea
breath testing using the Helifinder capsules, which con-
tained polyethylene glycol (PEG) 4000 to enhance the
dissolution of urea. The baseline breath sample was col-
lected in a white-labeled test tube through a straw, and
20 minutes after ingestion of the capsule with 50 mL of
water, a second breath sample was collected in a blue-
labeled test tube. The 13CO2 levels in the before and after
13C administration breath samples were analyzed using
an isotope ratio mass spectrometer (IRMS, Medichems,
Seoul, Korea). If the change ( 13C: ) from the base-
line (pre-ingestion) level at 20 minutes after ingestion was
2.0 or higher, the patient was determined as H. pylori-
infected, and non-infected if lower than 2.0 [12].
The second phase required collection of a pre-adminis-
tration breath sample in a special breath-sampling bag,
before ingestion of one film-coated 13C-urea tablet (UBiT)
with 100 mL of water. Subsequently, participants remained
in the left lateral decubitus position for 5 minutes upon
which they sat up to a sitting position for further 15 min-
utes, before the 20-minute breath sample was taken. The
13CO2 levels in these breath samples were analyzed by a
nondispersive isotope-selective infrared spectrophotometer
(NDIRS; UBiT-IR300; Otsuka Electronics, Osaka Japan)
and likewise, H. pylori infection was determined using 
13C( ), the calculated difference between pre-administra-
tion and 20-minute breath sample. A H. pylori-positive
result was given when the 13C was more than 2.5 ,
and H. pylori-negative when the 13C was less than
2.5 . We repeated the Helifinder test following the UBiT
test for 8 available cases after an additional 2-week wash-
out period. A rapid urease test (CKD Bio Hp, Seoul, Korea)
was performed during the endoscopic gastrointestinal biopsy
in some of the patients.
3. Statistical analysis
The comparison of the 13C-UBTs (Helifinder� versus
UBiT�) were tested by linear regression analysis and Pear-
son’s coefficient for correlation, Passing-Bablok comparison
methods, kappa testing for agreement, and chi-square test
using Analyse-it for Microsoft Excel (Analyse-It Software,
Ltd. Leeds, UK).
RESULTS
Of the 39 apparently healthy volunteers between the
age of 22 to 60 (mean±standard deviation, 37.6±9.75)
with a male to female ratio of 12:27 (Table 1), 19 were
positive by both Helifinder and UBiT methods with excel-
lent agreement between the two methods (weighted kappa
value, 1.0, Table 2). The DOB value of Helifinder (y, )
showed good agreement but with a proportional bias com-
pared to UBiT (x, ) by the Passing and Bablok method
(y=0.551x-0.255, r= 0.74, P<0.0001, Fig. 1). Initially, a
discrepant case with Helifinder-positive (13.97 ) and
UBiT�- negative (0.5 ) results was detected but, on
follow-up, both UBiT and Helifinder tests were positive
(42.3 and 13.6 , respectively). The rapid urease test
was performed during the endoscopic gastrointestinal biop-
sy in this patient and a positive rapid urease test result
supported the positive results from both urea breath tests.
The replicate study of Helifinder for the 8 available cases
also showed excellent agreement (y=0.972x+0.0141, r=
0.9, P=0.0023; kappa statistics, 1.0) with no significant
difference (P>0.05 by paired t-test).
DISCUSSION
There are many diagnostic tests available to date for
the detection of H. pylori infection, including endoscopic
gastrointestinal biopsy, campylobacter-like organism (CLO)
test, H. pylori culture, ELISA and the urea breath test.
Stringent conditions are required for H. pylori culture, so
this culture technique is not regarded as an appropriate
main diagnostic method. Moreover, most patients tend to
avoid the biopsies or CLO tests since a gastrointestinal
endoscopic procedure is necessary for the tests. Further-
more, given that H. pylori isn’t evenly dispersed among
the gastric mucosa, there is always the likelihood of false
negative results for the biopsy and CLO test. Hence, 13C-
UBTs proved to have a higher sensitivity and specificity
compared with biopsy and CLO test[12].
With the advent of this promising 13C-utilizing UBT, a
test that provides diagnosis for infection as well as deter-
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No. of patients with urea breat test
Positive Negative
Gender (No)
Male (12) 6 6
Female (27) 13 14
Total (39) 19 20
Table 1. Patient distribution of urea breath test-positive versus -
negative results
HeliFinder�
Negative Positive
UBT Method Total
UBiT�
Negative 20 0 20
Positive 0 19 19
Total 20 19 39
Table 2. Agreement of 13C-urea breath test results between He-
lifinder� and UBiT�
Fig. 1. Passing and Bablok comparison of Helifinder� and UBiT�
13C values ( ). Dashed lines show the 95% confidence limits of
the regression line.
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mining infective status after antibiotic treatment[6], vari-
ous alterations have been made to lower the costs, decre-
ase the amount of 13C-urea intake, reduce the number of
breath samples needed, shorten the duration between the
two breath samples and overall produce an easily appli-
cable, convenient, and accurate test. The Helifinder cap-
sules have accommodated many of these needs by not
increasing the costs despite using an expensive isotope
ratio mass spectrometer by lowering the 13C-urea dosage
to 38 mg, another benefit in itself. Using capsules with
PEG4000 enabled 13C-urea dose to be reduced and en-
hanced the dissolution of urea, which subsequently pro-
vided protection from the oral urease effect and contribut-
ed to the maintenance of satisfactory diagnostic quality.
Moreover, these capsules offered convenience for the ex-
aminee by omitting the lateral decubitus position step re-
quired in the previous tests, including the UBiT method,
and collecting only 10 mL of expired gas as opposed to
300 mL needed for the conventional method. The reduc-
tion in sample volume is an advantage when testing for
the elderly, children, and patients with pulmonary disease.
Nevertheless, education of the patients is imperative be-
cause this method uses test tubes and straws instead of
balloons.
The limitation of this study was that the confirmatory
tests were not performed for all cases and the relatively
small number of recruited patients. Nevertheless, we pro-
pose the Helifinder capsule test for clinical use based on
this head-to-head comparison study in the same individ-
uals, with excellent agreement with the validated urea
breath test (e.g. 0.76 with Helifinder and 1.4 with
UBiT; 6.27 with Helifinder and 7.6 with UBiT, etc).
In addition, the one inconsistent case in our study group
may suggest that UBiT may show false negative results,
which may be due to inappropriate positional changing
or inadequately exhaled breath samples.
We could conclude that in comparison to the conven-
tional UBiT (100 mg 13C-urea tablet) method, the new
low-dose capsule was appealing to a wide range of patients
including children and the elderly as well as being com-
parable in quality and cost. Therefore, the Helifinder� 13C-
UBT is considered to be a convenient and valid alterna-
tive to the conventional UBiT for the diagnosis of H. pylori
infection.
요 약
배경 : 요소호기검사법은 Helicobacter pylori 감염을 진단하는
데 있어서 정확하며 비침습적인 방법이다. 저자들은 최근 개발된
38 mg 저용량 13C-요소캡슐(Helifinder�)을 이용한 요소호기검
사의 임상적인 유용성을 평가하였다. 
대상 및 방법 : 임상시험 참여에 동의하고 서면 동의서에 서명
한 39명의 지원자를 대상으로 2004년 11월부터 2005년 1월까지
검사를 시행하였다. 대상자들은 38 mg 13C-요소캡슐을 사용한
요소호기검사를 시행한 후 최소 2주간의 간격을 두고 기존에 사
용되던 UBiT-IR300�를 사용한 방법과 비교검사를 하였다. 저용
량 요소캡슐은 질량분석기를 통해 20분 후 호기 표본을 분석하였
고 기존 방법에서는 적외선 분광광도계을 이용하여 분석하였다. 
결과 : Helifinder 방법은 요소용량을 줄였지만 UBiT-IR300
방법과 비교하여 모두 H. pylori 양성 19명, 음성 20명으로 두 검
사간 우수한 일치도를 보였다(weighted kappa value 1.0). 13C
값은 비례오차를 보였으나 좋은 일치도를 보였다(Passing and
Bablok method; y=0.551x-0.255, r=0.74, P<0.0001).
결론 : 새롭게 개발된 38 mg 저용량 13C-요소캡슐을 이용한
요소호기검사는 기존의 검사와 동등한 결과를 보였으며 더 편리
하고 경제적인 검사로서 Helicobacter 감염증 진단에 사용할 수
있는 유용한 검사라고 판단되었다.
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